Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 8/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | PTPRZ1 | P23471 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25944446 | 0.83 | SLC6A4 (0.38) | NAAACTSKSLC6A4SLC6A2SLC6A3 | |
| SCHEMBL21984758 | 0.79 | IDO1 (0.55) | NAAASLC6A4SLC6A2SLC6A3IDO1 | |
| SCHEMBL27246487 | 0.78 | IDO1 (0.51) | NAAASLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL21722847 | 0.78 | NAAA (0.44) | NAAACTSKSLC6A4SLC6A2SLC6A3 | |
| SCHEMBL27138919 | 0.78 | LMNA (0.36) | NAAACTSK | |
| SCHEMBL30945246 | 0.76 | SLC6A4 (0.45) | SLC6A4 | |
| SCHEMBL29277472 | 0.74 | ALDH1A1 (0.40) | NAAACTSKPTPRZ1 | |
| SCHEMBL25943837 | 0.74 | NAAA (0.36) | NAAACTSKSLC6A4SLC6A2SLC6A3 | |
| SCHEMBL25326344 | 0.74 | GPR119 (0.43) | — | |
| SCHEMBL25296511 | 0.73 | NAAA (0.38) | NAAACTSKSLC6A4SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199587-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2024-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199587-A1 | HETEROCYCLIC COMPOUNDS | CYP1B1, CYP1A1, CYP4B1 | NAAA 1979/4885CTSK 2643/4885PTPRZ1 3088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.